Pulse wave velocity is decreased in acromegaly compared to non-acromegaly study participants with similar cardiovascular risk profile.

Abstract

OBJECTIVE\nAcromegaly patients were reported to have an increased arterial stiffness that could contribute to the frequent cardiovascular complications in this population. The chronic excess of GH and IGF-1 may lead to arterial stiffening via different mechanisms, including hypertension, impaired glucose tolerance and dyslipidemia, however, it is not known whether the activation of GH/IGF-1 axis might influence arterial stiffening independently of cardiovascular risk factors. The objective of this prospective case-control study was to compare arterial stiffness assessed with pulse-wave velocity (PWV) in acromegaly versus non-acromegaly group with similar cardiovascular risk profile.\n\n\nDESIGN\nThis prospective case-control study included 27 patients with active acromegaly, who underwent the assessment of clinical, physiological, biochemical parameters and the evaluation of PWV with applanation tonometry. We used The epidemiology of cardiovascular disease in different regions of the Russian Federation study database (n\xa0=\xa0522) to establish a non-acromegaly control group with similar cardiovascular risk profile (n\xa0=\xa054). Non-acromegaly control participants underwent the same assessment as acromegaly patients except for the measurement of serum GH and IGF-1 levels. We compared PWV in acromegaly patients to the general non-acromegaly cohort and its subset, matched with acromegaly patients for cardiovascular risk factors. We also investigated the associations of PWV with clinical, physiological and biochemical parameters in acromegaly and non-acromegaly group using correlation and regression analysis with adjustment for age and sex.\n\n\nRESULTS\nAcromegaly patients had lower PWV (6.70 (5.75-7.65) m/s) compared to unmatched non-acromegaly control cohort (7.50 (6.70-8.57) m/s, p\xa0=\xa00.01) and to the non-acromegaly control group matched for cardiovascular risk factors (7.45 (6.73-8.60), p\xa0<\xa00.01). In non-acromegaly control group PWV was associated with BMI (ρ\xa0=\xa00.40, p\xa0<\xa00.01; β\xa0=\xa00.09, p\xa0<\xa00.01), obesity (r\xa0=\xa00.46, p\xa0<\xa00.01; β\xa0=\xa01.36, p\xa0<\xa00.01), systolic blood pressure (ρ\xa0=\xa00.60, p\xa0<\xa00.01; β\xa0=\xa00.05, p\xa0<\xa00.01), diastolic blood pressure (ρ\xa0=\xa00.62, p\xa0<\xa00.01; β\xa0=\xa00.07, p\xa0<\xa00.01), triglycerides (ρ\xa0=\xa00.55, p\xa0<\xa00.01; β\xa0=\xa00.58, p\xa0=\xa00.04), glucose (ρ\xa0=\xa00.54, p\xa0<\xa00.01; β\xa0=\xa00.70, p\xa0<\xa00.01) and diabetes (r\xa0=\xa00.40, p\xa0<\xa00.01; β\xa0=\xa01.10, p\xa0=\xa00.03), while in acromegaly group PWV was associated with IGF-1 expressed in mcg/ml (ρ\xa0=\xa0-0.49, p\xa0≤0.01; β\xa0=\xa0-0.002, p\xa0≤0.01) and in percentage of the upper limit of the normal (ρ\xa0=\xa0-0.47, p\xa0=\xa00.01; β\xa0=\xa0-0.005, p\xa0≤0.01) as well as with diuretics treatment (β\xa0=\xa0-1.17, p\xa0=\xa00.03).\n\n\nCONCLUSIONS\nPWV is decreased in acromegaly patients compared to non-acromegaly control participants with similar cardiovascular risk profile. Future studies need to explore the role of GH/IGF-1 axis in the regulation of arterial wall properties and the reliability of PWV as a prognostic marker of cardiovascular complications in acromegaly.